No headlines found.
No press releases found.
No news found.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
Cyclerion Therapeutics trades on the NASDAQ stock market under the symbol CYCN.
As of March 28, 2024, CYCN stock price climbed to $3.20 with 18,254 million shares trading.
CYCN has a market cap of $8.67 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, CYCN stock traded as high as $97.20 and as low as $1.75.
The top ETF exchange traded funds that CYCN belongs to (by Net Assets): VXF, ONEQ.
CYCN has underperformed the market in the last year with a return of -70.4%, while the SPY ETF gained +33.6%. In the last 3 month period, CYCN fell short of the market, returning -24.0%, while SPY returned +10.1%. However, in the most recent 2 weeks CYCN has outperformed the stock market by returning +6.3%, while SPY returned +1.7%.
CYCN support price is $2.79 and resistance is $3.37 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CYCN stock will trade within this expected range on the day.